Product image of Komboglyze (Metformin Hydrochloride, Saxagliptin) supplied by GNH India

Komboglyze

Active Ingredient:
Metformin Hydrochloride, Saxagliptin
Origin:
EU

Komboglyze (Metformin Hydrochloride, Saxagliptin)

Metformin Hydrochloride and Saxagliptin, the active ingredient in Komboglyze, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control.
GNH India supplies Komboglyze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Astrazeneca Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Komboglyze is an oral antidiabetic medication used to manage blood glucose in type 2 diabetes mellitus and related therapeutic pathways.

  • Type 2 diabetes mellitus: improves overall glycaemic control.
  • Adjunct to diet and exercise: helps achieve target HbA1c when lifestyle measures are insufficient.
  • Combination therapy: can be used with other antidiabetic agents for enhanced glucose lowering.

How It Works

  • Metformin Hydrochloride reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, while Saxagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), leading to elevated endogenous incretin levels that enhance glucose‑dependent insulin secretion and suppress glucagon release, together providing complementary glucose‑lowering effects.

Side Effects

Komboglyze may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal discomfort.
  • Diarrhea: loose stools often occurring early in therapy.
  • Abdominal pain: cramping or discomfort in the stomach area.
  • Headache: transient mild to moderate pain.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but life‑threatening metabolic complication.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
  • Skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating Komboglyze, several safety considerations should be reviewed.

  • Renal function: assess creatinine clearance to avoid accumulation.
  • Hepatic status: evaluate liver enzymes as impairment may increase risk.
  • Cardiac disease: monitor patients with heart failure closely.
  • Concomitant hypoglycaemic agents: adjust doses to prevent low blood sugar.
  • Elderly patients: start at lower doses and monitor tolerability.
  • Store at room temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Komboglyze can interact with various medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: heightened risk of severe hypoglycaemia.
  • Severe renal impairment: increased metformin exposure leading to lactic acidosis.
  • Iodinated contrast agents: may precipitate renal dysfunction.
  • Strong CYP3A4 inhibitors: elevate saxagliptin plasma levels.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may affect renal function when combined with metformin.
  • Diuretics: can alter fluid balance and renal clearance.
  • ACE inhibitors or ARBs: monitor renal parameters.
  • Beta‑blockers: may mask hypoglycaemic symptoms.
  • Alcohol: can potentiate metformin‑related lactic acidosis.

Frequently Asked Questions

Komboglyze is prescribed for the management of type 2 diabetes mellitus. It combines metformin, which improves insulin sensitivity, with saxagliptin, a DPP‑4 inhibitor that enhances insulin secretion, helping patients achieve better blood‑glucose control when diet and exercise alone are insufficient.

Metformin Hydrochloride lowers blood glucose primarily by decreasing hepatic glucose production and increasing peripheral uptake of glucose. It improves insulin sensitivity in muscle and fat tissues, thereby reducing the amount of glucose released into the bloodstream.

The dose of Komboglyze is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

The safety of Komboglyze in pregnancy and lactation has not been fully established. Metformin is sometimes used during pregnancy under specialist supervision, while saxagliptin is generally avoided. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Komboglyze, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Komboglyze offers a fixed‑dose combination of metformin and a DPP‑4 inhibitor, providing complementary mechanisms of action in a single tablet. Compared with metformin alone, it adds glucose‑dependent insulin secretion, and versus separate tablets, it simplifies dosing and may improve adherence.

Komboglyze tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Komboglyze is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the timing and frequency prescribed by their healthcare professional.

The most serious risks include lactic acidosis from metformin, especially in patients with renal impairment, and severe hypoglycaemia when combined with insulin or sulfonylureas. Rare but critical adverse events such as pancreatitis and serious skin reactions should also be monitored.

Komboglyze is contraindicated in patients with severe renal impairment, known hypersensitivity to metformin or saxagliptin, and those with a history of lactic acidosis. Caution is advised in individuals with hepatic disease, heart failure, or a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Saxagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT